Covalon Announces Official Launch into Vast Latin American Market at Prestigious Hospitalar Fair & Forum, South America’s L...
May 16 2016 - 9:02AM
Business Wire
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:
COV), an advanced medical technologies company, today announced
that it will officially enter the vast Latin American Market at
Hospitalar, Latin America’s largest and most prestigious medical
and healthcare trade event, taking place on May 17-20, 2016 in Sao
Paulo, Brazil.
Hospitalar attracts over 90,000 visitors from North, Central and
South America and is a must-attend on the agendas of hospital
administrators, doctors, nurses, distributors and other industry
professionals. The event is a meeting point for the healthcare
chain, the ideal space for showcasing innovations in products and
services.
“Latin America represents a strategic opportunity for Covalon to
utilize its proven business model used in other regions, such as
the Middle East, to enter the infection management, advanced wound
care and surgical dressings markets within the individual countries
in Central and South America,” said John R. Hands, Executive Vice
President of Covalon. “Hospitalar is the best place to officially
launch Covalon’s superior product line to the majority of the Latin
American medical thought leaders. Our products are uniquely
positioned to address many of the product gaps currently found in
the Latin American market, especially when one considers the
explosion of diabetic-related wounds in the region.”
Covalon offers infection management and advanced wound
management dressings for both acute and chronic wounds, including
its CovaWound™ ColActive® and SurgiClear™ brands that have strong
clinical evidence to support their superior efficacy in helping to
prevent infections in surgical procedures and chronic diabetic foot
wounds. ColActive and CovaWound when used together have the ability
to rapidly promote wound closure and healing in chronic wounds,
which remains an under-addressed market in Latin America.
“Our infection management and advanced wound care products have
been successfully helping patients and clinicians in the United
States, Middle East and Asian markets, and we are very excited
about the opportunity to bring that same success to doctors and
nurses in South America,” said Hands. “We are in the process of
engaging distribution partners in a number of Latin American
countries to expand our presence in the market and we expect to
accelerate this process at Hospitalar.”
Covalon will also be showcasing IV Clear™ Antimicrobial Vascular
Access Securement Dressing. IV Clear’s combination of chlorhexidine
and silver is proven to have a synergistic effect against some of
the most common hospital acquired infection bacteria1 and
SurgiClear’s soft silicone adhesive will not cause adhesive related
skin injury or pain during dressing changes2.
Covalon will be showcased at the Expo Center Norte, in the North
American Pavilion, Green Hall, Booth I-85 at Hospitalar, May 17-20
in Sao Paulo, Brazil.
About CovalonCovalon Technologies Ltd. researches,
develops and commercializes new healthcare technologies that help
save lives around the world. Covalon's patented technologies,
products and services address the advanced healthcare needs of
medical device companies, healthcare providers and individual
consumers. Covalon's technologies are used to prevent, detect and
manage medical conditions in specialty areas such as wound care,
tissue repair, infection control, disease management, medical
device coatings and biocompatibility. To learn more about Covalon,
visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or
implied in the forward-looking statements. Many risks are inherent
in the industry; others are more specific to the Company. Investors
should consult the Company's ongoing quarterly filings for
additional information on risks and uncertainties relating to these
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements
whether as a result of new information, further events or
otherwise.
1 A Laboratory Study of the Synergistic Effect of Chlorhexidine
and Silver, Blom, Kristina Werthen, Maria et al. American Journal
of Infection Control, Volume 43, Issue 6, S222 A Human Repeat Patch
Test Study, DiTizio et al.
http://www.wounds-uk.com/case-series/harrogate-2014-conference-posters
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160516005959/en/
Covalon Technologies Ltd.Brian Pedlar, 905-568-8400 x
233CEO,bpedlar@covalon.comToll free: 1-877-711-6055Web site:
www.covalon.comTwitter: @covalon
Covalon Technologies (TSXV:COV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Covalon Technologies (TSXV:COV)
Historical Stock Chart
From Sep 2023 to Sep 2024